Welcome to our dedicated page for Keycorp SEC filings (Ticker: KEY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing KeyCorp’s capital ratios, credit-loss provisions, and derivatives footnotes can consume hours. The bank’s 10-K regularly tops 300 pages, and each 8-K on loan sales or rate moves adds another layer of complexity. If you’ve ever wondered how to turn dense numbers into actionable insights, you’re not alone.
Stock Titan solves that problem. Our AI reads every KeyCorp SEC document the moment it hits EDGAR and delivers plain-English explanations. Whether you need a KeyCorp quarterly earnings report 10-Q filing or want KeyCorp Form 4 insider transactions real-time, we surface exactly where net interest income shifted, which segments drove fee growth, and when executives bought shares.
- AI-powered summaries translate credit-quality tables and Basel III capital metrics into clear language—KeyCorp SEC filings explained simply.
- Real-time alerts for KeyCorp insider trading Form 4 transactions and KeyCorp executive stock transactions Form 4.
- Side-by-side trend tools for KeyCorp earnings report filing analysis across multiple quarters.
- Quick links to the KeyCorp annual report 10-K simplified and the latest KeyCorp proxy statement executive compensation.
- Context on every KeyCorp 8-K material events explained—from dividend declarations to unexpected credit updates.
The result? You monitor loan-portfolio shifts before they impact earnings, spot insider sentiment without sifting through PDFs, and grasp how interest-rate swings alter guidance. Understanding KeyCorp SEC documents with AI means spending minutes, not days, to make informed lending, trading, or asset-allocation decisions.
Form 4 filing summary – KeyCorp (KEY), 07/01/2025: Director Barbara R. Snyder converted 35,955 deferred shares (transaction code M) into an equal number of common shares. The conversion increased her directly held common-share position to 71,632 shares. No open-market purchase or sale price was reported because the shares derive from KeyCorp’s Directors’ Deferred Share Sub-Plan, where each deferred share is economically equivalent to a common share. Following the transaction, Snyder still holds 177,901 deferred shares that remain subject to the plan. The filing also notes that direct ownership totals include roughly 175 common shares obtained through the June 2025 dividend-reinvestment program, and deferred-share holdings include about 2,765 dividend-equivalent units accrued during the same period. As there was no disposition of shares and the transaction merely settles a long-standing equity award, the impact on KeyCorp’s public float and insider sentiment is modest.
Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name “Dyadic Applied BioSolutions.” The filing clarifies that the legal corporate name remains “Dyadic International, Inc.,” the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished—not filed—thereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.
The Form 4 filing reports that Chemours Company (CC) director Courtney Mather was awarded 2,292 deferred stock units (DSUs) on 30 June 2025. Each DSU equals one share of common stock and will be settled in the first month after the director leaves the board. The award is recorded at a reference price of $11.45 per unit. After the grant, Mather directly owns 2,292 derivative securities; no sales or additional purchases of common stock were disclosed. Apart from this routine director compensation grant, the filing contains no other material transactions or changes in ownership.
Form 4 filing overview: On 06/30/2025, MAIA Biotechnology, Inc. (ticker MAIA) granted director Cristian Luput a package of stock options under the company’s 2021 Equity Incentive Plan.
- Options granted: 21,350 options to purchase common shares.
- Exercise price: $1.80 per share.
- Vesting schedule: 100% vested immediately on the grant date.
- Expiration: 06/30/2035 (10-year term).
- Post-transaction holdings: Luput now holds 21,350 derivative securities directly.
No non-derivative share transactions were reported, and the filing was made individually by the director. The grant represents routine equity compensation designed to align director incentives with shareholder value, but it modestly increases the company’s fully diluted share count.
On 30 June 2025, Wintrust Financial Corp. (WTFC) director Brian A. Kenney reported the acquisition of 420 common shares under the company’s Director’s Deferred Fee and Stock Plan, as disclosed in a Form 4 filing. The shares were credited at a price of $112.46, increasing Kenney’s direct beneficial ownership to 11,214 WTFC shares. The transaction is coded “A,” indicating an award rather than an open-market purchase, and no derivative securities were involved. While routine in nature, the filing slightly increases insider ownership and may be viewed as a signal of continued alignment between the director and shareholder interests.
Morgan Stanley Finance LLC (ticker: MS) has filed Amendment No. 1 to Pricing Supplement No. 8,667 for a $440,000 follow-on issuance of Dual Directional Buffered PLUS notes (CUSIP 61778KD61) that will be consolidated with the original $310,000 tranche, bringing the total outstanding to $750,000. The five-year structured notes, due 28 Jun 2030, are unsecured and fully guaranteed by Morgan Stanley.
Key economic terms
- Issue price: $1,000; minimum denomination $1,000.
- Estimated value on pricing date: $943.80 (reflecting structuring & hedging costs).
- Underlying indices: DJIA (INDU 42,982.43), Nasdaq-100 (NDX 22,237.74) and Russell 2000 (RTY 2,136.185).
- Leverage factor: 140% on any positive performance of the worst-performing index.
- Absolute return participation: 100% of any decline up to 20%, effectively capping gain from this feature at 20%.
- Buffer: 20% downside protection; losses begin once the worst performing index falls below 80% of its initial level.
- Minimum maturity payment: 20% of principal.
- No periodic coupons; payment occurs only at maturity.
Cash-flow profile
- Upside scenario: final level > initial level → principal plus 1.4× index appreciation.
- Moderate downside: final level between 80% and 100% of initial → principal plus up to 20% gain.
- Severe downside: final level < 80% of initial → 1:1 loss beyond buffer, floor at 20% of principal.
Placement economics: Investors pay a 3.5% sales commission ($35 per note); net proceeds to Morgan Stanley are $965 per note. The notes will not be listed, and secondary liquidity depends solely on MS & Co., which may discontinue market making at any time.
Risk highlights
- Principal at risk; no interim interest.
- Performance driven solely by the worst performing index, eliminating diversification benefits.
- Credit exposure to Morgan Stanley; notes rank pari passu with other unsecured obligations.
- Estimated value below issue price indicates negative carry at inception.
- Tax treatment uncertain; counsel views notes as prepaid financial contracts, but IRS may disagree.
Strategic context: At $0.75 million aggregate size, the issuance is immaterial to Morgan Stanley’s capital structure but offers the bank low-cost funding while transferring market risk to investors.
FAQ
What is the current stock price of Keycorp (KEY)?
What is the market cap of Keycorp (KEY)?
What is the core business of KeyCorp?
How does KeyCorp serve its clients?
What types of financial products does KeyCorp offer?
In which regions does KeyCorp primarily operate?
What makes KeyCorp's business model unique?
How does KeyCorp maintain operational excellence?
How does KeyCorp differentiate itself from competitors?
What role does KeyCorp play in community development?
